News

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

  • SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT).
    07/11/2024

7 Growth Stocks to Buy for Under $5 for Massive Gains

  • With growth stocks under $5, the focal point is rather obvious: putting woodwork on the ball as aggressively as possible. Of course, swinging for the fences comes with significant risks.
    07/11/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Elutia Inc. (ELUT) can hold. Click on Rating Page for detail.

The price of Elutia Inc. (ELUT) is 3.78 and it was updated on 2024-07-27 07:01:08.

Currently Elutia Inc. (ELUT) is in undervalued.

News
    
News

3 Best Breakout Stocks Worth a Buy for Attractive Returns

  • BRC (BRCC), Costamare (CMRE) and Elutia (ELUT) have been selected as the breakout stocks for today.
    Wed, Jun. 26, 2024

Elutia Announces $13.26 Million Registered Direct Offering

  • SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.
    Mon, Jun. 17, 2024

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

  • EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market
    Mon, Jun. 17, 2024

Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript

  • Elutia, Inc. (NASDAQ:ELUT ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matthew Lambert - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia First Quarter 2024 Financial Results Conference Call.
    Sun, May. 12, 2024

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

  • SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024, at 3:00 p.m. ET (12:00 p.m. PT).
    Wed, Apr. 24, 2024
SEC Filings
SEC Filings

Elutia Inc. (ELUT) - 4

  • SEC Filings
  • 06/25/2024

Elutia Inc. (ELUT) - 8-K - Current report

  • SEC Filings
  • 06/18/2024

Elutia Inc. (ELUT) - 8-K - Current report

  • SEC Filings
  • 06/17/2024

Elutia Inc. (ELUT) - 424B5

  • SEC Filings
  • 06/17/2024

Elutia Inc. (ELUT) - 4

  • SEC Filings
  • 06/12/2024

Elutia Inc. (ELUT) - 4

  • SEC Filings
  • 06/10/2024

Elutia Inc. (ELUT) - 8-K - Current report

  • SEC Filings
  • 06/07/2024

Elutia Inc. (ELUT) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/13/2024

Elutia Inc. (ELUT) - 8-K - Current report

  • SEC Filings
  • 05/09/2024

Elutia Inc. (ELUT) - DEFA14A

  • SEC Filings
  • 04/22/2024

Elutia Inc. (ELUT) - DEF 14A

  • SEC Filings
  • 04/22/2024

Elutia Inc. (ELUT) - 8-K - Current report

  • SEC Filings
  • 04/01/2024

Elutia Inc. (ELUT) - 4

  • SEC Filings
  • 03/14/2024

Elutia Inc. (ELUT) - 10-K - Current report

  • SEC Filings
  • 03/11/2024

Elutia Inc. (ELUT) - 8-K - Current report

  • SEC Filings
  • 03/07/2024
More Headlines
News

Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript

  • Elutia, Inc. (NASDAQ:ELUT ) Q4 2023 Results Conference Call March 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Randy Mills - President and Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Fourth Quarter and Full-Year 2023 Financial Results Call.
  • 03/07/2024

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

  • SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • 03/07/2024

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

  • SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
  • 02/22/2024

Elutia Regains Compliance with Nasdaq Listing Requirements

  • SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq's market value of listed securities requirement and majority independent board requirement. As a result, the Company now satisfies all applicable requirements for continued listing with Nasdaq, and the Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”
  • 01/10/2024

Elutia Inc. (ELUT) Upgraded to Buy: Here's Why

  • Elutia Inc. (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  • 11/17/2023

Elutia, Inc. (ELUT) Q3 2023 Earnings Call Transcript

  • Elutia, Inc. (NASDAQ:ELUT ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants David Carey - Finn Partners Randy Mills - President and Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Q3 2023 Financial Results Call.
  • 11/17/2023

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

  • - Anticipate 510(k) filing for transformational Drug-Eluting Biomatrix CanGarooRM in Fourth Quarter SILVER SPRING, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2023.
  • 11/13/2023

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

  • - Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced it completed the divestiture of its Orthobiologics business unit to Berkeley Biologics LLC, a wholly owned subsidiary of GNI Group Ltd.
  • 11/09/2023

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

  • SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on Monday, November 13, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
  • 11/06/2023

Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference

  • SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a panel at the Cantor Global Healthcare Conference. The panel discussion will take place in New York on Wednesday, September 27, 2023, at 8:00 am ET.
  • 09/20/2023

Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M

  • Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.
  • 09/19/2023

Elutia Announces Private Placement for Proceeds Up to $26 Million

  • – Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it has entered into a securities purchase agreement for a private placement (PIPE) financing that is expected to result in initial gross proceeds to the Company of approximately $10.5 million, before deducting offering expenses.
  • 09/19/2023

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

  • SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced the divestiture of the Company's Orthobiologics business unit to Berkeley Biologics LLC, a wholly owned subsidiary of GNI Group Ltd. Elutia will receive cash proceeds of up to $35 million, comprised of an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over a five-year period. The transaction is expected to close in the fourth quarter of 2023.
  • 09/18/2023
Unlock
ELUT Ratings Summary
ELUT Quant Ranking